Klaria Pharma Holding AB (publ) ("Klaria" or the "Company") announces that the Company has received approximately SEK 2.2 million in subscription commitments without preferential rights in the ongoing rights issue of units of up to approximately SEK 147.6 million (the "Rights Offering"). No compensation will be paid for these subscription commitments, and they are included within the framework of the existing guarantee structure of a total of approx. SEK 111.1 million, corresponding to 75.3 percent of the Rights Offering. Furthermore, the Board of Directors has decided to extend the subscription period until November 6, 2026 in light of a strong interest from shareholders and investors and the accompanying request for extended time to have the opportunity to subscribe for units in the Rights Offering with preferential rights.
Below is an updated timetable for the Rights Offering. As a result of the extended subscription period, the period for trading in unit rights is also extended to November 3. All other terms and conditions remain as before.
| Event | Date |
| Trading in unit rights | October 14-November 3, 2026 |
| Subscription period | October 14-November 6, 2026 |
| Trading in paid subscribed units (BTU) | October 14-November 24, 2026 |
| Expected announcement of the preliminary outcome | November 9, 2026 |
| Expected announcement of the final outcome | November 10, 2026 |
More information about the Rights Offering can be found on the Company's website, www.klaria.com, and on the issue page www.ii.se/klaria-rights-issue-of-units-2026/